ARA-290
ARA-290
Also known as: Cibinetide, Helix B Surface Peptide, HBSP
Overview
Key Facts
Primary Goal: An 11-amino acid synthetic peptide derived from the B helix of erythropoietin
An 11-amino acid synthetic peptide derived from the B helix of erythropoietin. Selectively activates the innate repair receptor (IRR) to promote tissue protection and repair without erythropoietic (blood cell) stimulation. Half-Life ~2 minutes (rapid clearance, prolonged tissue effects) Typical Dose 2–4 mg Frequency 1x daily Cycle Length 4-12 weeks
Dosing Information
Half-Life
~2 minutes (rapid clearance, prolonged tissue effects)
Typical Dose
2–4 mg
Frequency
1x daily
Cycle Length
4-12 weeks
Administration Routes:
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
Multiple Phase 2 clinical trials completed for sarcoidosis-associated neuropathy and diabetic neuropathic pain. Demonstrated improved corneal nerve fiber density and reduced neuropathic symptoms. Developed by Araim Pharmaceuticals with promising safety and tolerability data.
Frequently Asked Questions
Common questions about ARA-290
UK-Specific Information
Exclusive data points and guidance for UK residents using ARA-290
UK Lab Testing
US Lab Testing
Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.